Market open

Immunic/$IMUX

14:30

22:10

05:45

13:25

21:00

1D1W1MYTD1Y5YMAX

About Immunic

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Ticker

$IMUX

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

New York, United States

Employees

Website

imux.com

Immunic Metrics

BasicAdvanced

$90M

-

-$1.12

1.88 -

Price and volume

Market cap

$90M

Beta

1.88

52-week high

$1.84

52-week low

$0.97

Average daily volume

889K

Financial strength

Current ratio

2.709

Quick ratio

2.564

Long term debt to equity

0.451

Total debt to equity

0.451

Management effectiveness

Return on assets (TTM)

-90.90%

Return on equity (TTM)

-216.24%

Valuation

Price to book

2.19

Price to tangible book (TTM)

2.19

Price to free cash flow (TTM)

-1.13

Growth

Earnings per share change (TTM)

-62.58%

3-year earnings per share growth (CAGR)

-33.83%

What the Analysts think about Immunic

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Immunic stock.

Immunic Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Immunic Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Immunic News

AllArticlesVideos

Immunic eyes transformative year ahead for MS therapy vidofludimus calcium - ICYMI

Proactive Investors·4 days ago

Immunic eyes key data readout from multiple sclerosis trial in 2025

Proactive Investors·1 week ago

Immunic's IMU-856 shows potential in gastrointestinal health trials - ICYMI

Proactive Investors·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $IMUX

$

Capital at risk

Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Immunic stock?

Immunic (IMUX) has a market cap of $90M as of January 15, 2025.

What is the P/E ratio for Immunic stock?

The price to earnings (P/E) ratio for Immunic (IMUX) stock is 0 as of January 15, 2025.

Does Immunic stock pay dividends?

No, Immunic (IMUX) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Immunic dividend payment date?

Immunic (IMUX) stock does not pay dividends to its shareholders.

What is the beta indicator for Immunic?

Immunic (IMUX) has a beta rating of 1.88. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.